COMPOSITION:
Each film-coated tablet contains 400 mg of sofosbuvir and 100 mg of velpatasvir.
Sofosbuvir is a nucleotide analog that works by inhibiting the HCV NS5B polymerase enzyme, which is essential for viral replication.
Velpatasvir is an NS5A inhibitor that blocks the activity of the NS5A protein, which is involved in viral replication and assembly.
INDICATIONS
LuciSoVe is a fixed-dose combination of sofosbuvir, a hepatitis C virus (HCV) nucleotide analog NS5B polymerase inhibitor, and velpatasvir, an HCV NS5A inhibitor, and is indicated for the treatment of adults and pediatric patients 3 years of age and older with chronic HCV genotype 1,2, 3, 4, 5, or 6 infection :
• without cirrhosis or with compensated cirrhosis.
• with decompensated cirrhosis for use in combination with ribavirin.
DOSAGE AND USE:
• Recommended dosage in adults: One tablet (400 mg of sofosbuvir and 100 mg of velpatasvir) taken orally once daily with or without food.
• Recommended dosage in pediatric patients 3 years and older: Recommended dosage is based on weight. Refer to Table 2 of the full prescribing information for specific dosing guidelines based on body weight.
• For pediatric patients less than 6 years of age, administer LuciSoVe oral pellets with food.
• HCV/HIV-1 coinfection: For patients with HCV/HIV-1 coinfection, follow the dosage recommendations in the table 1 of the full prescribing information.
• For treatment-naïve and treatment-experienced liver transplant recipients without cirrhosis or with compensated cirrhosis (Child Pugh A), the recommended regimen is LuciSoVe once daily for 12 weeks.
• If used in combination with ribavirin, follow the recommendations for ribavirin dosing and dosage modifications.
STORAGE:
In a dry place and store at 20℃ to 25℃.
MANUFACTURED AND MARKETED BY:
LUCIUS PHARMACEUTICALS(LAO) CO., LTD
No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos
WARNINGS:
Keep medicine out of reach of Children. Do not administer LuciSoVe during Pregnancy and Lactation.
Original article, if reprinted, please indicate the link to this article: https://lucius-pharmaceuticals.com/drug/sofosbuvir-400mg-velpatasvir-100mg/
Related News
-
RASONQUE™ (Daraxonrasib) Clinical Trials, Distribution & Value in Precision Oncology
Clinical Trials of RASONQUE™ (Daraxonrasib) The clinical development of RASONQUE™ (Daraxonrasib) has…
2026-10-05
-
RASONQUE™(Daraxonrasib): Dosage Instructions, Side Effects, FAQ & Myths
How to Take RASONQUE™ (Daraxonrasib) Safely and Effectively Take it exactly as…
2026-10-03
-
Turning Off the Signal That Fuels Cancer: RASONQUE™ (Daraxonrasib) Overview
Turning Off the Signal That Fuels Cancer: RASONQUE™ (Daraxonrasib) Overview When Every…
2026-10-01
-
Understanding ATTR-CM: A Patient-Friendly Guide to Transthyretin Amyloidosis Cardiomyopathy
1. Experience: What Living with ATTR-CM Can Feel Like Symptoms of ATTR-CM…
2026-09-04
-
LuciOdevi FAQs, Myths, Clinical‑Trial Data & Medication Distribution Guide | Lucius Pharmaceuticals
Frequently Asked Questions About LuciOdevi Q1. What is LuciOdevi?A: LuciOdevi is an…
2026-08-14
-
Unveiling New Possibilities in the Treatment of Cholestatic Liver Disorders: LuciOdevi 400mcg Developed by Lucius Pharmaceuticals
Introduction Cholestatic liver disorders cover a broad, hard‑to‑treat group of hepatobiliary illnesses…
2026-08-11



